(Top) Myeloma plasma cells eat significant glutamine within the tumor microenvironment, thereby preventing the full activity of BCMA-targeting CAR T cells unless they are engineered to overexpress the glutamine transporter Asct2. (Bottom) These Asct2-overexpressing CAR T cells are highly active in a fully immunocompetent, genetically engineered mouse model of myeloma.